DexCom, Inc. DXCM reported second-quarter 2026 adjusted earnings per share (EPS) of 70 cents, which beat the Zacks Consensus ...

Shares of DexCom Inc. surged 11.95% to $83.45 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.70% to 7,489.72 and the Dow Jones ...

Targets converting approximately 50% of the U.S. customer base to the G7 15-day system by the end of 2026 to drive long-term ...

Q2 2026 earnings call highlights: revenue/EPS, raised guidance, G7 15-Day rollout, CMS timing & buybacks—get key takeaways now.

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...

This was the stock's third consecutive day of gains.

During the quarter, we had the opportunity to host many of you at our 2026 Investor Day, where we highlighted our substantial market opportunity and introduced a new long-term ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 ...

SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported second-quarter profit of $249.1 million. The San Diego-based company said it had profit of 64 cents per share. Earnings, ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. Shareholder ...

Shares of DexCom Inc. DXCM rallied 7.22% to $77.98 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.51% to 7,533.77 and Dow ...